The two companies I've chosen are Sarepta Therapeutcis and Viking Therapeutics:

Viking Ratios (2022/2021): Current Ratio: 7.61/23.98 Quick Ratio: 7.09/23.03 Debt to Equity: 0.16/0.04 Return on Equity: -42.92%/24.63% EPS: -$0.90/-$0.71 Price to earnings ratio: -10.7/-6.39 Dividend payout ratio: (no dividends) Sarepta Ratios (2022/2021): Current Ratio: 4.13/5.75 Quick Ratio: 3.8/5.34 Debt to Equity: 7.13/2.39 Return on Assets: -22.79%/-14.75% Return on Equity: -117.22%/-69.15% EPS: -$8.03/--$5.83 Price to earnings ratio: -7.71/-27.49 Dividend payout ratio: (no dividends)

1a) Calculate all the ratios your group considers relevant for all the years presented ( 3 of IS and 2 of BS) covering Chapters 2, 3, 4 and 5 for both companies you select. 1b) DuPont analysis, fully disaggregated, for the current and previous years. Your group's analysis should Include: 2a) Identification of most significant balance sheet accounts and explanation as to why they are appropriate for the industry. 2b) Analysis of Short-Term liquidity 2c) Analysis of Operating Performance and Efficiency 2d) Analysis of Long-Term Solvency. 2e) Analysis of Profitability, including DuPont, commenting on each of the three components of the calculation 2f) Summary of the companies' financial health. (In thousands, except share and per share amounts) Viking Therapeutics, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts) Consolidated Balance Sheets (in thousands, except share and per share amounts) Sarepta Therapeutics, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share data)